The groundbreaking success of Sildenafil undeniably revolutionized the medication landscape, but placing funds in companies strongly reliant on unbranded versions presents a challenging picture. Although early profits were significant, the cessation of patents and the emergence of cheaper alternatives have diminished sales. Therefore, a thorough an